IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA

IASO Biotherapeutics (IASO Bio) announced that the US FDA granted both RMAT designation and FT designation to its investigational new drug BCMA CAR-T CT103A, Equecabtagene Autoleucel, for relapsed/refractory multiple myeloma.